JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online August 18, 2009, 10.2967/jnumed.109.062356
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.109.062356v1
50/9/1533    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Dutour, A.
Right arrow Articles by Marec-Bérard, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dutour, A.
Right arrow Articles by Marec-Bérard, P.
Journal of Nuclear Medicine Vol. 50 No. 9 1533-1540
© 2009 by Society of Nuclear Medicine
doi: 10.2967/jnumed.109.062356

Basic Science Investigation

18F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model

Aurélie Dutour1,3, Anne-Valérie Decouvelaere*,2,3, Jacques Monteil*,4, Marie-Eve Duclos5, Olivier Roualdes5, Raphaël Rousseau*,1,3,5,6 and Perrine Marec-Bérard*,3,6

1 Inserm, U590, Lyon, France; 2 Département d'Anatomopathologie et Cytologie, Lyon, France; 3 Centre Léon Bérard, Lyon, France; 4 Service de Médecine Nucléaire, Centre Hospitalier Universitaire Dupuytren, Limoges, France; 5 Université de Lyon, Lyon, France; and 6 Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France

Correspondence: For correspondence or reprints contact: Raphaël Rousseau, Institut d'Hématologie-Oncologie Pédiatrique, 1 Place Du Professeur Joseph Renaut, 69373 Lyon, Cedex 08, France. E-mail: dutoura{at}lyon.fnclcc.fr

Assessment of osteosarcoma response to neoadjuvant chemotherapy is performed by histopathologic analysis after surgical resection of the primary tumor. The purpose of this study was to evaluate whether 18F-FDG PET could be a noninvasive surrogate to histopathologic analysis and allow for earlier response evaluation to neoadjuvant chemotherapy in osteosarcoma. Methods: Metabolic response to neoadjuvant chemotherapy was assessed in immunocompetent rats with a preestablished orthotopic osteosarcoma using 18F-FDG PET before and after receiving 2 doses of ifosfamide. Comparison was then made by assessing histologic responses on euthanized animals. Results: Maximum standardized uptake value (SUVmax) measured by 18F-FDG PET after 2 doses of chemotherapy was correlated to histologic classification (P < 0.01). An SUVmax less than 15 corresponded to good responders, whereas an SUVmax greater than 15 but less than 20 and an SUVmax greater than 20 corresponded to partial responders or nonresponders, respectively. A 40% decrease in SUVmax between the first and second 18F-FDG PET scans distinguished between partial and good response to chemotherapy. Conclusion: Determination of SUVmax using semiquantitative 18F-FDG PET predicts response to neoadjuvant chemotherapy earlier than does histologic analysis.

Key Words: osteosarcoma • histologic response • 18F-FDG PET • metabolic response • SUVmax

* Contributed equally to this work.

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.